Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2011
|
| Online Access: | http://hdl.handle.net/20.500.11937/10830 |
| _version_ | 1848747641281708032 |
|---|---|
| author | Eiermann, W. Pienkowski, T. Crown, J. Sadeghi, S. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Riva, A. Buyse, M. Drevot, P. Taupin, H. Mackey, J. |
| author_facet | Eiermann, W. Pienkowski, T. Crown, J. Sadeghi, S. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Riva, A. Buyse, M. Drevot, P. Taupin, H. Mackey, J. |
| author_sort | Eiermann, W. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| first_indexed | 2025-11-14T06:52:22Z |
| format | Journal Article |
| id | curtin-20.500.11937-10830 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:52:22Z |
| publishDate | 2011 |
| publisher | American Society of Clinical Oncology |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-108302017-02-28T01:33:31Z Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial Eiermann, W. Pienkowski, T. Crown, J. Sadeghi, S. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Riva, A. Buyse, M. Drevot, P. Taupin, H. Mackey, J. 2011 Journal Article http://hdl.handle.net/20.500.11937/10830 American Society of Clinical Oncology restricted |
| spellingShingle | Eiermann, W. Pienkowski, T. Crown, J. Sadeghi, S. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Riva, A. Buyse, M. Drevot, P. Taupin, H. Mackey, J. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title_full | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title_fullStr | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title_full_unstemmed | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title_short | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| title_sort | phase iii study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: bcirg-005 trial |
| url | http://hdl.handle.net/20.500.11937/10830 |